Physicians managing chronic migraine may be interested in new comparative patient-reported data from the FORWARD study, which evaluated treatment satisfaction with onabotulinumtoxinA versus topiramate. In...
At the 2026 American Academy of Neurology Annual Meeting in Chicago, IL, investigators presented real-world evidence evaluating whether glucagon-like peptide-1 receptor agonists influence healthcare...
The results from a recent randomized controlled trial showed that ultrasound-guided sphenopalatine ganglion (SPG) and greater occipital nerve blocks are equally effective in reducing headache frequency,...
This phase 4 study assessed the long-term safety and tolerability of once-daily oral rimegepant (75 mg) in adults with episodic migraine to inform clinicians about its preventive treatment profile.
A phase 3 randomized trial evaluated the efficacy and safety of fremanezumab for preventive treatment of episodic migraine in children and adolescents, addressing a significant evidence gap in pediatric...
A phase 4 TANDEM trial in the United States evaluated whether ubrogepant for acute migraine treatment can be safely added to atogepant and used daily for preventive therapy in adults with episodic migraine,...
A large cohort study found no significant association between migraines, their subtypes, or frequency and Parkinson disease (PD) risk in women 45 years and older, suggesting migraines may not contribute to...
